HeartBeam, Inc.
NASDAQ · us_market
No AI summary generated yet for this ticker.
HeartBeam, Inc. operates as a medical technology company that focuses on developing and commercializing electrocardiogram solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility. The company develops HeartBeam System, a cable-free and ambulatory 12L ECG that captures the heart's electrical signals from three dimensions for high-fidelity data collection and advanced diagnostics for arrhythmia assessment which consists of credit card sized 3D ECG recording device, a patient application, a physician portal, and powerful cloud-based algorithms. HeartBeam, Inc. was incorporated in 2015 and is based in Santa Clara, California.
HeartBeam (BEAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
HC Wainwright & Co. analyst Yi Chen maintains HeartBeam (NASDAQ:BEAT) with a Buy and lowers the price target from $5.5 to $2.5.
Benchmark analyst Bill Sutherland maintains HeartBeam (NASDAQ:BEAT) with a Speculative Buy and lowers the price target from $8 to $5.
LOS ANGELES, CA - May 14, 2026 (NEWMEDIAWIRE) - HeartBeam (NASDAQ: BEAT) reported first-quarter 2026 operational and financial results highlighted by the launch of its initial commercial partnerships in key U.S. markets, progress in its heart attack ...
Moby summary of HeartBeam, Inc.'s Q1 2026 earnings call
Moby summary of HeartBeam, Inc.'s Q1 2026 earnings call
HeartBeam, Inc. (BEAT) Q1 2026 Earnings Call May 13, 2026 4:30 PM EDTCompany ParticipantsRobert Eno - CEO, Chief Business Officer & DirectorBryan...
HeartBeam Inc (BEAT) advances its market presence with key partnerships and robust financing, despite early-stage commercialization challenges.
HeartBeam Inc (BEAT) advances its market presence with key partnerships and robust financing, despite early-stage commercialization challenges.
HeartBeam (NASDAQ:BEAT) released first-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call transcripts and financial data. Visit https://www.benzinga.com/apis/ to learn more. The full earnings call is available at https://viavid.webcasts.com/starthere.jsp?ei=1761581&tp_key=a64f57a332 Summary Heartbeam Inc reported a successful first quarter, with a focus on commercialization and growth ini
HeartBeam (NASDAQ:BEAT) released first-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call transcripts and financial data. Visit https://www.benzinga.com/apis/ to learn more. The full earnings call is available at https://viavid.webcasts.com/starthere.jsp?ei=1761581&tp_key=a64f57a332 Summary Heartbeam Inc reported a successful first quarter, with a focus on commercialization and growth ini
SANTA CLARA, Calif., May 13, 2026--HeartBeam Reports First Quarter 2026 Results
2026-05-13. The following slide deck was published by HeartBeam, Inc.
Total Heart Intelligence… Wherever You Are FIRST QUARTER 2026 FINANCIAL RESULTS CONFERENCE CALL MAY 13, 2026 NASDAQ: BEAT ...
Total Heart Intelligence… Wherever You Are FIRST QUARTER 2026 FINANCIAL RESULTS CONFERENCE CALL MAY 13, 2026 NASDAQ: BEAT ...
HeartBeam (NASDAQ:BEAT) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) by 14.29 percent. This is a 33.33 percent increase over losses of $(0.18) per share from the
LOS ANGELES, CA - May 11, 2026 (NEWMEDIAWIRE) - HeartBeam (NASDAQ: BEAT) announced the initiation of a pilot study evaluating its investigational on-demand 12-lead ECG patch in approximately 50 patients with suspected coronary artery disease at two h...
SANTA CLARA, Calif., May 11, 2026--HeartBeam Initiates Pilot Study of First On-Demand 12-Lead ECG Patch to Detect Ischemia Outside the Clinic
HeartBeam, Inc. announced the initiation of a pilot study evaluating its novel on-demand 12-lead ECG patch in patients with suspected coronary artery disease. The study is being conducted at two...
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 125.5K | $153.08K | 0.00% | Unchanged | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-14upcoming | -0.09 | — | — |
| 2026-05-13 | -0.13 | -0.12 | +11.11% |
| 2026-03-12 | -0.14 | -0.14 | -1.82% |
| 2025-11-13 | -0.15 | -0.15 | +3.23% |
| 2025-08-13 | -0.16 | -0.15 | +6.25% |
| 2025-05-13 | -0.15 | -0.18 | -20.00% |
| 2025-03-13 | -0.19 | -0.18 | +5.26% |
| 2024-11-07 | -0.17 | -0.19 | -11.76% |
| 2024-08-14 | -0.16 | -0.19 | -15.15% |
| 2024-05-09 | -0.15 | -0.17 | -13.33% |
| 2024-03-20 | -0.14 | -0.13 | +4.88% |
| 2023-11-14 | -0.13 | -0.13 | — |
| 2023-08-10 | -0.20 | -0.16 | +20.00% |
| 2023-05-11 | -0.33 | -0.50 | -53.06% |
| 2023-03-16 | -0.46 | -0.45 | +3.23% |
| 2022-11-10 | -0.34 | -0.44 | -29.41% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BEAT | -0.79% | -40.48% | -63.54% | -48.53% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -3.76% | -35.84% | -60.10% | -61.22% |